Regular treatment
ApprovedSmall molecule
Innovent Biologics (Suzhou) Co. Ltd.Regular treatment is one of 76 small molecule programs targeting Cerebral Small Vessel Disease. It is currently in Approved.
3
Indications
3
Total Trials
0
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Regular treatment
Innovent Biologics (Suzhou) Co. Ltd.Approved
Cosentyx
NovartisPreclinical
Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Victoza
Novo NordiskPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cerebral Small Vessel Disease1 trial
Remote Ischemic Conditioning on Cerebral Small Vessel Disease
Unknown status·—·N/A·NCT04816500·60 enrolled
Ulcerative Colitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Regular treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details